4-METHOXY-ISOPHTHALIC ACID DERIVATIVE HAVING A PHARMACOLOGICAL ACTIVITY IN THROMBOEMBOLIC DISORDERS AND A PROCESS FOR THE PREPARATION THEREOF

Abstract: 3-carbamoyl-(3'-picolyl)-4-methoxy-1-benzamide of formula is a pharmaceutical agent for the prevention and treatment of thromboelmbolic disorders due to increased blood platelet aggregation.

Description: BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel organic substance included in the class comprising substituted or non-substituted isophthalic acid picolylamides, which is pharmacologically active and able to inhibit the blood platelet aggregation in vitro and in vivo and to control the thrombo­ embolic disorders produced by a modified blood platelet activity. The present invention also relates to a process for the synthesis of said substance. The compound forming the object of the present invention is a 4-methoxy-isophthalic acid picolyl­ amide whose chemical denomination is 3-carbamoyl(3'-­ picolyl)-4-methoxy-1-benzamide or, in an equivalent nomenclature, N-N'-(3'-picolyl)-4-methoxy-isophthal­ amide, the formula of which is C₁₅H₁₅N₃O₃ cor­ responding to a mole weight of 285,3. The conventional structure formula thereof can be represented as follows: In the following description, the above defined compound will be briefly indicated as G 619. 2. Prior Art It is well known, particularly from US patent 3973026, Italian patent 1016005, US patent 4294833 and German patent 3113150, that the organic compounds of the class comprising substituted or non-substituted isophthalic acid picolylamides shown an anti-coagulant, fibrinolitic and blood platelet anti-aggregant activity. Among said compounds N-N'-bis-(3-picolyl)-4-methoxy-isophthal­ amide monohydrate under a crystal form has shown a particularly high activity (see German patent 3113150, which compound is briefly indicated with the denomination "picotamide monohydrate". It has now been surprisingly found that the compound object of the present invention has a still higher and more rapid pharmacological activity of the same type, particularly as far as the inhibition of blood platelet aggregation is concerned. On the basis of the knowledge avail­ able at the state of the prior art for the compounds included in the above-mentioned class, and parti­ cularly for anhydrous picotamide and picotamide monohydrate, it was not to be expected as obvious that an elimination of the 3-picoline radical on the amide nitrogen atom in 1-position would produce a nett increase of the pharmacological activity and biodisposability, nor could it be expected that such activity increase would be free from negative side effects, as on the contrary it has resulted with the compound object of the present invention. SUMMARY OF THE INVENTION It is an object of the present invention to provide a novel 4-methoxy-isophthalic acid picolylamide which has a higher activity and pharma­ cological efficiency, in view of the positive effects found after absorption by the animal and human organism. A further object of the present invention is a process for obtaining the above-mentioned novel substance. Another object of the present invention is the therapeutical use of the above-mentioned novel substance under the various pharmacologically active forms thereof for preventing and treating thromboembolic diseases. DETAILED DESCRIPTION OF THE INVENTION The compound according to the present inven­ tion of the above illustrated formula, can be obtained by reacting a 4-methoxy-isophthalic mono­ loweralkyl ester with 3-picolylamine, so as to obtain the respective mono-picolylamide. Then the mixed anhydride which is formed as an inter­ mediate is reacted in an anhydrous solvent with ethylchloroformate, and in the presence of a proton acceptor and under an ammonia gas stream, it is possible to obtain the compound according to the invention. The following schema illustrates the reactions: In the following preparation example which is merely illustrative and not limitative of the present invention, the process is described by which it is possible to obtain the product of the invention by synthesis. Possible modifications which are obvious to those skilled in the art, fall within the scope of the invention. EXAMPLE OF PREPARATION a) Step 1: synthesis of mono(3-picolylamide) (I). A mixture of 4,7 ml 4-methoxy-isophthalic acid monomethylester and 47 ml of 3-picolylamine is maintained for 24 hours at a temperature of from 55 to 65°C, preferably 60°C. At the end of this time, it is cooled and the reaction container is placed in a freezing mixture such that the temperature is maintained about 0°C during the following acidification, which is carried out by glacial acetic acid or with HCl 5 N to the extent that a pH from 3,5 to 5,5 depending on the situation is reached, to obtain, in other words, the total precipitation of compound I. The precipitate is recovered by suction, thoroughly washed with distilled water and crystalized from organic solvent. It is used as such for the follow­ ing step. b) Step 2: synthesis of 3-carbamoyl(3'-­ picolyl)-methoxy-1-benzamide (II). A mixture of 2,6 ml of compound I, obtained as previously described and suspended into chloro­ form, with 5,6 ml triethylamine (as a proton acceptor), is slowly additioned with 5,6 ml ethyl­ chloroformate under stirring at 0°C. After standing at 0°C for half an hour, the reaction mixture is saturated by ammonia gas, then left at room temperature for three hours. At the end of this time, the white precipitate of the desired product (compound II) is recovered by suction filtering, washed with water and crystallized from a suitable solvent. The product thus obtained shows a melting point of 190-191°C at the Kofler bench. The mole structure of G619 has been determined by X-ray analysis, by using an automatic diffracto­ meter Enrat-Nonius CAD-4 having four circles with graphite monochromator. The data have been processed by a Gould SEL 32/27 computer and with the aid of a video terminal Tektronix 4125. The structure of the molecule resulting from the analysis, is illustrated in figure 1. Figure 2 represents the position of the molecules in the crystal in a projection perpendi­ cular to the crystallographic axis y. Each molecule is characterized by an intra­ molecular hydrogen bond between O20 and N12 (bond length 2.63 A) and two intermolecular hydrogen bonds both relating to the amide nitrogen N9 and oxygen O8 respectively of one molecule (bond length 2.94 A) and oxygen oil of another molecule (bond length 2.95 A). The intermolecular hydrogen bonds are illustrated with dotted lines in figure 2. The fractional atomic coordinates as well as the values of bond distances and angles relating to the molecule of G 619 are referred in the follow­ ing tables. PHARMACOLOGICAL TESTS The compound object of the present invention has been tested to ascertain the acute toxicity, bio-disponibility and interference with the blood platelet function in vitro and in vivo by carrying out tests in all cases in comparison with another molecule, picotamide monohydrate, which is included in the same class of products, and the pharma­ cological activity of which is already known (see German patent 3113150). Example 1 Blood platelet anti-aggregate activity in vitro . Platelet aggregation was induced in rabbit "platelet rich plasma" (PRP) by employing as aggre­ gant agents adenosine diphosphate (ADP) and arachi­ donic acid (AANa) after incubation at 37°C for 10 minutes with the compounds under test. The activity is expressed as the concentration able to decrease by 50% (IC₅₀) the maximum amplitude (AM) of the aggregation curve so obtained, with respect to the aggregation curve as obtained with control plasmas incubated only with buffers. The results of the tests effected with ADP and AANa are hereinafter referred: Blood platelet aggregation from ADP G 619 IC₅₀=1,25x10⁻⁴M Picotamide monohydrate IC₅₀=9,3x10⁻⁴M Blood platelet aggregation from AANa G619 IC₅₀=2,69x10⁻⁵M Picotamide monohydrate IC₅₀=7,9x10⁻⁵M From the above illustrated results it can be observed that compound G 619 shows a platelet anti-aggregant activity which is from 3 to 7 times higher than that of picotamide monohydrate, depend­ ing on the aggregant agent used. Example 2 Blood platelet anti-aggregant activity in vivo . New Zealand rabbits which had been held fasting for twelve hours with water ad libitum , were administered with G 619 and picotamide mono­ hydrate at various dosages in a gum acacia suspension. To the control rabbits only gum acacia was administered. After 30 minutes from treatment the animals were anaesthetized with sodium pentothal (30 mg/Kg i.v.) and blood was taken from the carotid artery, rendered incoagulable with sodium citrate at 3,8% and centrifuged at 1400 rpm for 15 minutes in order to obtain the platelet rich plasma (PRP). On said PRP the platelet aggregation was induced by arachidonic acid and the corresponding aggrega­ tion curve was recorded using a Born aggregometer. The activity is indicated as the dose able to decrease by 50% (ID₅₀) the maximum amplitude (AM) of the aggregation curve of plasma of treated animals with respect to that of plasma from control animals, the following results being obtained: G 619 ID₅₀=25 mg/KG Picotamide monohydrate ID₅₀=78 mg/KG From the above results it can be seen that the activity of G 619 is about 3 times higher than that of picotamide monohydrate. Example 3 Per os absorption in rat. Per os absorption tests have been carried out in rat after a sole administration of 100 mg/Kg in gum acacia suspension. The determinations of the blood levels of the two substances at various times have been effected on plasma using a high pressure liquid phase chromatograph and indicated as γ /ml. The values referred hereinafter represent the average of 8 determinations: It can be noted that compound G 619 shows an absorption from 8 (½ hour) to 19 times (2 hours) higher than that of picotamide monohydrate. Example 4 Acute toxicity (DL₅₀). The compound of the present invention was subjected to acute toxicity tests on two animal species and two administration routes. The animals were treated per os or endovenously in a sole administration, have been held under observa­ tion for seven days after treatment by recording the symptomatology and the number of deaths. The results, referred in the following table, are indicated as the dose which produces the death of 50% of the treated animals (DL₅₀) calculated by statistical method: It can be observed that toxicity, shown prevailingly with a depressive symptomatology, appears to be very low in proportion to the above mentioned pharmacological activity. Example 5 Blood platelet anti-aggregant activity in vitro on human blood and evaluation of the mechanism of action. The blood platelet anti-aggregant activity of G619 was studied in comparison with picotamide on human platelet rich plasma (PRP), wherein the platelet aggregation was induced with ADP, collagen, AANa and U46619 after incubation at 37°C for ten minutes with the compounds under test. The results, indicated as a concentration able to decrease by 50% (IC₅₀) the maximum amplitude of the aggrega­ tion curve obtained with control plasma incubated only with the buffer, are the following: In order to investigate the mechanism of action of G619 the production of malondialdehyde (MDA) and thromboxane B₂ (TxB₂) after stimulation with collagen 1 µg/ml was measured on human PRP. The results, indicated as IC₅₀, are as follows: The production of 6-keto-PGFla was also measured after stimulation of human PRP with collagen 1 µg/ml. An increase by 100-150% in the production of 6-keto-PGFla was observed starting from concentrations of 10⁻⁶ M, in correspondance with which picotamide showed itself to be hardly efficient. The results show that G619 is a blood platelet anti-aggregant agent with a power of action higher by a factor of 10 with respect to the picotamide in platelet aggregations induced in human PRP. Example 6 Blood platelet anti-aggregant activity on human volunteers. On healthy human volunteers of both sexes aging from 31 to 53 the blood anti-aggregant activity was evaluation by per os treatment at a 500 mg sole dose, taking the blood samples before treatment and after 1 - 2 - 4 - 6 hours. The platelet aggregation was induced in PRP using ADP as aggregant agent at a concentration of 2x10⁻­ ⁶M following the method illustrated in example 2. The platelet anti-aggregant activity reported in quantitative terms in the following table, was calculated as percent inhibition of the aggrega­ tion curve after treatment with respect to the control: The results as obtained and herein illustrated shown in favour of G619 a higher and quicker platelet anti-aggregant activity, the maximum activity for G619 being namely of 53,8% and obtained after two hours after treatment, whereas for picotamide monohydrate a maximum of 41,1% was observed only after four hours. CONCLUSIONS The results as obtained and referred in the foregoing examples evidence substantial dif­ ferences in positive activities in favour of compound G619 with respect to picotamide monohydrate. Moreover, this higher in vitro and in vivo pharmacological activity is associated to a lower toxicity and an improved biodisponibility as examples 3, 4 and 5 show. Furthermore, said substantial positive differences in favour of compound G619 were not to be expected on the basis of the simple elimination of 3-picoline radical on the nitrogen atom in 1 position. Compound G619, in view of its high activity associated to low toxicity, excellent tollerability and biodisponibility, can be useful in human therapy for prevention and treatment of various thrombo­ embolic disorders, particularly cerebro-vascular disorders, myocardial infarct, artery and phlebo­ thrombosis, pulmonary embolism, general arterio­ sclerotic conditions, cardiosurgery and general surgery. For said use various pharmaceutical forms can be employed, containing from 10 to 500 mg of active agent, examples of which can be mentioned merely as preferred embodiments: a) Orally: capsules, tablets, pills containing 10 to 500 mg, for a daily dosage of 50-2000 mg/day; b) Parenterally: sterilized endovenous and intramuscular injectable phials containing 10 to 50 mg for a daily dosage of 10 to 150 mg/day; c) Rectally: suppositories containing 10 to 500 mg for a daily dosage of 50 to 2000 mg/day. The pharmaceutical formulation may obviously contain, besides the active agent, usual pharma­ ceutically acceptable vehicles and adjuvants, as is well known in the pharmaceutical field. It is also obvious that the administration forms of compound G619 and the respective dosage patterns can be varied according to the clinical circum­ stances and experience of physicians.

Claims: 1. 3-carbamoyl-(3'-picolyl)-4-methoxy-1-benzamide of formula: 2. A process for the preparation of 3-carbamoyl-­ (3'-picolyl)-4-methoxy-1-benzamide comprising: reacting 4-methoxy-1-isophthalic acid mono-lower­ alkyl ester with 3-picolylamine at a temperature from 55 to 65°C; acidifying the reaction product to pH 3,5 to 5,5 at a temperature as low as 0°C and recovering the precipitate 4-methoxy-isophthalic acid monopicolylamide; reacting said monopicolyl­ amide in anhydrous solvent with ethylchloroformate at a temperature as low as 0°C in the presence of a proton acceptor, saturating with ammonia gas and recovering the precipitate 3-carbamoyl-­ (3'-picolyl)-4-methoxy-1-benzamide. A process according to claim 2, wherein said mono-loweralkyl ester is mono-methylester and the temperature in the reaction with 3-picolyl­ amine is 60°C. 4. A process according to claim 2, wherein said anhydrous solvent is chloroform and said proton acceptor is triethylamine. 5. An active agent for the prevention and treatment of thromboembolic disorders due to blood platelet aggregation in mammals, consisting of 3-carbamoyl-(3'-picolyl)-4-methoxy-1-benzamide. 6. A pharmaceutical composition comprising an amount of 3-carbamoyl-(3'-picolyl)-4-methoxy-­ 1-benzamide therapeutically effective for the prevention and treatment of thromboembolic disorders due to blood platelet aggregation, and a pharmaceutically compatible carrier. 7. Use of 3-carbamoyl-(3'-picolyl)-4-methoxy-­ 1-benzamide for the manufacture of a medicament for the prevention and treatment of thromboembolic disorders due to blood platelet aggregation. Version of claims for Austria, Greece and Spain under Art. 167(2)(a). 1. A process for the preparation of 3-carbamoyl-­ (3'-picolyl)-4-methoxy-1-benzamide comprising: reacting 4-methoxy-1-isophthalic acid mono-lower­ alkyl ester with 3-picolylamine at a temperature from 55 to 65°C; acidifying the reaction product to pH 3,5 to 5,5 at a temperature as low as 0°C and recovering the precipitate 4-methoxy-isophthalic acid monopicolylamide; reacting said monopicolyl­ amide in anhydrous solvent with ethylchloroformate at a temperature as low as 0°C in the presence of a proton acceptor, saturating with ammonia gas and recovering the precipitate 3-carbamoyl-­ (3'-picolyl)-4-methoxy-1-benzamide. 2. A process according to claim 1, wherein said mono-loweralkyl ester is mono-methylester and the temperature in the reaction with 3-picolyl­ amine is 60°C. 3. A process according to claim 1, wherein said anhydrous solvent is chloroform and said proton acceptor is triethylamine. 4. Use of 3-carbamoyl-(3'-picolyl)-4-methoxy-­ 1-benzamide for the manufacture of a medicament for the prevention and treatment of thromboembolic disorders due to blood platelet aggregation.

Inventors: DE REGIS, MASSIMO, MANNUCCI, EMANUELA
Applicants: MANETTI & ROBERTS ITALO BRIT
Application year: 1986
Main classification: C07D213
IPC codes: A61K31, C07D213, A61P7